Clinical Trial

Study to Detect Dendritic Cell Recruitment in Human Retina

Study acronym: ICG-002
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 12, 2025 (before its estimated November 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this study is to develop an optimal method to detect the immune cells (cells that protect the human body against diseases) in association with abnormal conditions of the retina (light sensitive tissue in the back of the eye) that will be relevant to diseases such as age related macular degeneration (AMD), mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or mild AD. The main objectives of this study are: 1. Establish Optimal Method for Retinal Imaging of Dendritic Cells (DCs) 2. Safety and Tolerability of ICG infusion in normal healthy, older adult volunteers, in participants with AMD (Dry AMD with Geographic Atrophy (GA)), and in participants who have received a diagnosis of either Mild Cognitive Impairment (MCI) due to AD, or mild AD
Trial Details
NCT Number NCT06872658
Lead Sponsor MindImmune Therapeutics, Inc.
Collaborators: Syneos Health, CHU de Quebec-Universite Laval
Conditions Dry Age Related Macular Degeneration, Mild Cognitive Impairment (MCI), Alzheimer Disease
Enrollment 15 participants
Start Date 2025-05-01
Primary Completion 2025-11-01 (estimated)
Study Completion 2026-01-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-12